Wipfli Financial Advisors’s Ginkgo Bioworks DNA Stock Holding History

Wipfli Financial Advisors’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$13K	Buy	+100	New	+$11.9K	﹤0.01%	1744

Other funds holding DNA

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Wipfli Financial Advisors's DNA Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in Ginkgo Bioworks (DNA) in Q3 2022: 100 shares worth $13K. The stake represents ﹤0.01% of the portfolio and ranks #1744 among its holdings.

278 funds tracked by Wall St. Rank hold DNA as of Q3 2022.

Wipfli Financial Advisors held 100 shares of Ginkgo Bioworks worth $13K as of Q3 2022.
Ginkgo Bioworks was a new Wipfli Financial Advisors position in Q3 2022.
Ginkgo Bioworks made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #1744 holding.
278 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.